Gamma-Irradiated Fowl Cholera Mucosal Vaccine: Potential Vaccine Candidate for Safe and Effective Immunization of Chicken Against Fowl Cholera

Dessalegn, Bereket; Bitew, Molalegne; Ali, Destaw Asfaw; Khojaly, Esraa; Ibrahim, Saddam Mohammed; Abayneh, Takele; Gelaye, Esayas; Unger, Hermann; Wijewardana, Viskam

doi:10.3389/fimmu.2021.768820

Cited by 9 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cross-linked polyacrylic polymers (Carbopol) can enhance the time of mucosal surface adhesion antigen and induce systemic antigen-specific IgG responses after intranasal vaccination ( Coucke et al, 2009 ). MONTANIDE™ Gel 01 (SEPPIC, France) is based on the stable gel polymers of sodium polyacrylate in water, and it prolongs the residence time of the vaccine in the nasal mucosa ( Deville et al, 2012 ; Li et al, 2019 ; Dessalegn et al, 2021 ). Pattern recognition receptor agonists have been extensively studied as mucosal adjuvants and can bind to pathogen recognition receptors on dendritic cells to activate downstream immune signals ( Velasquez et al, 2010 ; Hjelm et al, 2014 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice

Hua

Chang²,

Zhang³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Pseudorabies virus (PRV) not only causes great economic loss to the pig industry but also seriously threatens the biosafety of other mammals, including humans. Since 2011, PRV mutant strains have emerged widely in China, and the classical Bartha-K61 vaccine cannot confer complete protection for pigs. PRV mainly infects pigs via the respiratory tract. Intranasal immunization with PRV has received more attention because intranasal vaccination elicits systemic and mucosal immune responses. To induce systemic and mucosal immune responses against PRV, we developed a combination adjuvant as a delivery system for intranasal vaccine, which was formulated with MONTANIDE™ Gel 01 and CVCVA5. In comparison to naked antigen of inactivated PRV, single Gel 01 adjuvanted inactivated antigen and single CVCVA5 adjuvanted inactivated antigen, intranasal inactivated PRV vaccine formulated with the combination adjuvant induced greater mucosal IgA immunity and serum antibody responses (IgG, IgG1, and IgG2a). Furthermore, the production of the Th1-type cytokine IFN-γ and the Th2-type cytokine IL-4 indicated that the cellular and humoral responses to the intranasal vaccine were improved by the combination adjuvant. In addition, the intranasal vaccine formulated with the combination adjuvant induced long-term T lymphocyte memory with increased central (CD62L+CD44+) and effector (CD62L–CD44+) memory subsets of both CD4 and CD8 T cells in nasal-associated lymphoid tissue. Intranasal challenge with virulent PRV in mice showed that the protective efficacy of the intranasal PRV vaccine was improved by the combination adjuvant compared with the other single-adjuvanted vaccines. In summary, these data demonstrated that Gel 01 combined with the CVCVA5 adjuvant induced a synergistic effect to improve mucosal immunity and protective efficacy of the intranasally inactivated PRV vaccine in mice. It represents a promising vaccination approach against PRV infection.

show abstract

Section: Discussionmentioning

confidence: 99%

“…MONTANIDE TM Gel 01 (SEPPIC, France) is a mucoadhesive polymeric adjuvant that can improve the safety and efficacy of mucosal vaccination (Deville et al, 2012;Li et al, 2019;Dessalegn et al, 2021). Gel 01 is based on a dispersion of highly stable gel particles of sodium polyacrylate in 10.3389/fmicb.2022.976220 water.…”

Section: Introductionmentioning

confidence: 99%

Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice

Hua

Chang²,

Zhang³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Immune responses and the protection in a mouse model were evaluated and found that both live attenuated vaccines (71%) and inactivated vaccines (51%) could not provide complete protection against homologous serotypes and did not protect against heterologous serotypes [ 11 ]. To address the above research questions, researchers have evaluated new types of vaccine such as subunit vaccines and DNA vaccines [ 12 – 15 ]. However, the correct folding, post-translational modification of proteins and harsh storage conditions still limit the development of related vaccines.…”

Section: Introductionmentioning

confidence: 99%

Recombinant-attenuated Salmonella enterica serovar Choleraesuis vector expressing the PlpE protein of Pasteurella multocida protects mice from lethal challenge

Zhou,

Tian,

Tian

et al. 2023

BMC Vet Res

View full text Add to dashboard Cite

Background Bacterial surface proteins play key roles in pathogenicity and often contribute to microbial adhesion and invasion. Pasteurella lipoprotein E (PlpE), a Pasteurella multocida (P. multocida) surface protein, has recently been identified as a potential vaccine candidate. Live attenuated Salmonella strains have a number of potential advantages as vaccine vectors, including immunization with live vector can mimic natural infections by organisms, lead to the induction of mucosal, humoral, and cellular immune responses. In this study, a previously constructed recombinant attenuated Salmonella Choleraesuis (S. Choleraesuis) vector rSC0016 was used to synthesize and secrete the surface protein PlpE of P. multocida to form the vaccine candidate rSC0016(pS-PlpE). Subsequently, the immunogenicity of S. Choleraesuis rSC0016(pS-PlpE) as an oral vaccine to induce protective immunity against P. multocida in mice was evaluated. Results After immunization, the recombinant attenuated S. Choleraesuis vector can efficiently delivered P. multocida PlpE protein in vivo and induced a specific immune response against this heterologous antigen in mice. In addition, compared with the inactivated vaccine, empty vector (rSC0016(pYA3493)) and PBS immunized groups, the rSC0016(pS-PlpE) vaccine candidate group induced higher antigen-specific mucosal, humoral and mixed Th1/Th2 cellular immune responses. After intraperitoneal challenge, the rSC0016(pS-PlpE) immunized group had a markedly enhanced survival rate (80%), a better protection efficiency than 60% of the inactivated vaccine group, and significantly reduced tissue damage. Conclusions In conclusion, our study found that the rSC0016(pS-PlpE) vaccine candidate provided good protection against challenge with wild-type P. multocida serotype A in a mouse infection model, and may potentially be considered for use as a universal vaccine against multiple serotypes of P. multocida in livestock, including pigs.

show abstract

“…Conventionally, for making the H9N2 IWV vaccine, H9N2 AIV is generally inactivated with formalin or β-propiolactone, which are poor in cellular and mucosal immune responses. However, recently a gamma-irradiated inactivated vaccine against fowl cholera enhances strong mucosal immunity after intranasal vaccination in chickens (Dessalegn et al 2021). This strategy may be also practical in the H9N2 IWV vaccine.…”

Section: Inactivated Vaccinementioning

confidence: 99%

Development of immune response against H9N2 avian influenza after vaccination

Xue

View full text Add to dashboard Cite

Xue, P. (2023). Development of immune response against H9N2 avian influenza after vaccination. PhD thesis, Wageningen University, the Netherlands.The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spilled over from animals to humans is a catastrophe killing more than six million people so far according to World Health Organization (WHO). Like SARS-CoV-2, the respiratory virus, H9N2 avian influenza virus (AIV), can also spill over from animals to humans, and is endemic in poultry flocks in several regions of the world. Some researchers are concerned that H9N2 AIV may be a spark to the emergence of the next influenza pandemic, either directly crossing the species barrier or through the donation of internal genes to a pandemic virus. Like dealing with SARS-CoV-2, vaccination is the main and most effective strategy to control H9N2 AIV. However, most vaccination programs against H9N2 AIV have shown to be ineffective in poultry in practice. Therefore, my project was 1) to figure out what factors may interfere with the H9N2 vaccine efficacy to sufficiently reduce transmission in poultry, 2) to come up with some ideas to improve the vaccine efficacy, and 3) to explore the mechanisms that influence the vaccine efficacy. In chapter 2, I went to several poultry farms for more than three months to collect surveillance data for H9N2 vaccination failure. The data suggests that maternal-derived antibodies (MDAs) may be one of reasons for H9N2 vaccination failure in poultry, which was further corroborated by animal experiments in broilers and specific pathogen-free (SPF) chickens in laboratory in the same chapter 2. In chapter 3, I developed a CpG ODN-based adjuvant that could help the H9N2 inactivated whole virus (IWV) vaccine overcome MDAs, triggering potent humoral immune responses and cytokinesis mRNA expression. In chapter 4, in order to stop transmission of H9N2 AIV, I used turkey herpesvirus (HVT) to express H9 HA protein. The recombinant virus (rHVT-H9) successively induced strong humoral and cellular immune responses, reducing virus shedding and transmission even in the presence of MDAs. In chapter 5, I explored some mechanisms of MDAs interference and found that only complete MDAs interfered with immune responses to vaccination instead of the antigen-binding portion (F(ab) 2 ) or the Fc-binding portion (Fc). In addition, type I chicken interferons (ch-IFNs) helped the H9N2 IWV vaccine overcome MDAs interference inducing potent humoral immune responses. Finally, in chapter 6, I discussed avian immune response after vaccination, the mechanisms of MDAs interference, new measurements of vaccine efficacy against transmission of H9N2 AIV and strategies to improve vaccine efficacy to stop transmission of H9N2 AIV in poultry. Overall, this thesis provides a deeper understanding of H9N2 vaccination failure in poultry and may spark some ideas to stop transmission of respiratory viruses. 20 subtype H9N2 does not prevent virus transmission in chickens. J Virus Erad, 7, 100055. Dadras, H., S. Nazifi & M....

show abstract

Gamma-Irradiated Fowl Cholera Mucosal Vaccine: Potential Vaccine Candidate for Safe and Effective Immunization of Chicken Against Fowl Cholera

Cited by 9 publications

References 30 publications

Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice

Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice

Recombinant-attenuated Salmonella enterica serovar Choleraesuis vector expressing the PlpE protein of Pasteurella multocida protects mice from lethal challenge

Development of immune response against H9N2 avian influenza after vaccination

Contact Info

Product

Resources

About